Kevin Cottle, APRN
Family · South Jordan, UTNPI 1245440478
Payments from drug & device makers
Across 115 payments — averaging $17.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$616
- Lilly USA, LLC$399
- Novo Nordisk$110
- Merck$103
- GSK$90
- Tris Pharma Inc$85
- plus $649 from 23 others
What the payments were for
- Food & beverage$2,04299%
- Education$111%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 32 | $616 |
| Lilly USA, LLC | 24 | $399 |
| Novo Nordisk | 7 | $110 |
| Merck | 6 | $103 |
| GSK | 6 | $90 |
| Tris Pharma Inc | 4 | $85 |
| Boston Scientific | 2 | $67 |
| Sanofi-aventis U.S. LLC | 3 | $47 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $44 |
| Alkermes, Inc. | 2 | $41 |
| Idorsia Pharmaceuticals US Inc | 3 | $40 |
| Corium, LLC | 2 | $39 |
| Mannkind Corporation | 2 | $38 |
| Neurelis, Inc. | 2 | $31 |
| Supernus Pharmaceuticals, Inc. | 2 | $30 |
| Biohaven Pharmaceuticals, Inc. | 1 | $27 |
| AstraZeneca | 2 | $25 |
| Ultragenyx Pharmaceutical Inc. | 1 | $24 |
| Eisai Inc. | 1 | $23 |
| Boehringer Ingelheim | 1 | $22 |
| Medtronic | 1 | $22 |
| Hologic Sales And Service, LLC | 1 | $18 |
| Dexcom, Inc. | 1 | $18 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $18 |
| Abbott | 1 | $16 |
| Sanofi Pasteur Inc. | 1 | $15 |
| Apria Healthcare LLC | 1 | $15 |
| Seqirus USA Inc | 1 | $14 |
| Cranial Technologies, Inc | 1 | $13 |
How this compares
$2,053 in reported general payments places this provider in the 80th percentile of 1,460 family providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 38 | $47,623 |
| JardianceEmpagliflozin | 27 | $24,477 |
| OzempicSemaglutide | 23 | $22,708 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $8,032 |
| Breo ElliptaFluticasone/Vilanterol | 15 | $6,427 |
| MovantikNaloxegol Oxalate | 11 | $4,477 |
| Omeprazole | 130 | $2,745 |
| Fluoxetine Hcl | 65 | $2,062 |
| Gabapentin | 102 | $1,699 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 47 | $1,661 |
| Atorvastatin Calcium | 160 | $1,471 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 45 | $1,162 |
| Duloxetine Hcl | 50 | $1,149 |
| Bupropion XlBupropion Hcl | 50 | $1,137 |
| Losartan Potassium | 90 | $930 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity | $399 | $47,62338 claims |
| Boehringer IngelheimJardiance | $22 | $24,47727 claims |
| Novo NordiskOzempic | $110 | $22,70823 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $90 | $14,45927 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,460 family providers in Utah.
Other family in South Jordan
- Shannon FordSouth Jordan$186K
- Riley WorthSandy$1.1M
- Katrina BawdenSalt Lake City$446K
- Cortnee RomanSalt Lake City$374K
- Jared ThorleySalt Lake City$368K
- Stephanie GodfreyLindon$358K
- Mary SteinbackSalt Lake City$189K
- Jennalyn MayeuxSalt Lake City$151K
- Brett RawlinsKaysville$149K
- Shelby MillerSandy$140K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.